Affordable Access

[Statistical analysis of variations in total cholesterol, HDL, HDL2, HDL3, LDL-cholesterol, VLDL-triglycerides, apo-A and apo-B lipoproteins in dyslipidemias during antilipemic therapy].

Authors
  • Melloni, G F
  • Scarazatti, E
  • Garanzelli, P
  • Melloni, R
Type
Published Article
Journal
Bollettino della Società italiana di biologia sperimentale
Publication Date
Jan 30, 1985
Volume
61
Issue
1
Pages
7–14
Identifiers
PMID: 3884023
Source
Medline
License
Unknown

Abstract

In our study, bezafibrate in short-acting formula and long-acting formula, administered to hyperlipidaemic patients, resulted in a significant lowering of atherogenic lipids and lipoproteins (chol.-T, LDL and VLDL-chol., apolipoprotein B and VDLD-TR), and a marked increase in the levels of HDL, HDL2, HDL3-chol. and apolipoprotein A with a protective action as regards vascular atherosclerotic damage. The long-acting formula showed a greater effectiveness.

Report this publication

Statistics

Seen <100 times